Robert Singal, MD
Interventional Cardiology · Plantation, FLNPI 1275504847
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,169 of the $26,616 with a category attached, or 64.5%. 33 manufacturers reported payments, led by Novartis at 37.4% of the total. Reporting peaked in 2019 at $9,974 and has fallen 71.4% since, to $2,854 in 2025.
Across 386 payments — averaging $68.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Abbott$5K
- Medtronic$5K
- Boston Scientific$1K
- Boehringer Ingelheim$763
- Amgen$606
- plus $4K from 27 others
Across 2 payments — averaging $8642.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
What the payments were for
- Speaking & faculty fees$8,96034%
- Travel & lodging$4752%
- Food & beverage$17,16965%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 48 | $9,957 |
| Abbott | 63 | $5,394 |
| Medtronic | 47 | $4,939 |
| Boston Scientific | 15 | $1,029 |
| Boehringer Ingelheim | 32 | $763 |
| Amgen | 39 | $606 |
| Inari Medical, Inc. | 9 | $539 |
| E.r. Squibb & Sons, L.L.C. | 23 | $343 |
| Atricure, Inc. | 3 | $341 |
| Abiomed | 4 | $315 |
| Merck | 17 | $291 |
| Johnson & Johnson | 17 | $290 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $282 |
| AstraZeneca | 13 | $230 |
| Cardiovascular Systems Inc. | 2 | $189 |
| Bayer | 10 | $186 |
| Terumo Medical Corporation | 2 | $157 |
| Pfizer | 6 | $113 |
| Novo Nordisk | 5 | $109 |
| Edwards Lifesciences | 1 | $98 |
| Penumbra, Inc. | 3 | $84 |
| Cvrx, Inc. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Cordis US CORP. | 2 | $45 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Preventice Services, LLC | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Vital Connect, Inc | 1 | $16 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$9,318
- COBALT DR MRI SURESCAN$2,225
- Confirm Rx$1,528
- Micra$1,238
- WATCHMAN Access System$801
- Quadra Assura CRT Defibrillator$777
- Quadra Allure MP RF CRT Pacemkr$748
- TYRX$704
- Fortify Assura, Ellipse ICD$494
- Assurity Pacemaker$440
- FLOWTRIEVER CATHETER, S$389
- CT THROMBECTOMY SYSTEM KIT$389
- JARDIANCE$250
- Optis Coronary Imaging System$177
- R2P MISAGO$138
- Quartet CRT Lead$135
- LINQ II$128
- SYNERGY ABLATION SYSTEM$125
- EPI-SENSE GUIDED COAGULATION SYS$120
- Impella$119
How this compares
$26,616 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $289,763 |
| EntrestoSacubitril/Valsartan | 70 | $77,014 |
| Repatha SureclickEvolocumab | 79 | $75,526 |
| OzempicSemaglutide | 59 | $61,078 |
| XareltoRivaroxaban | 28 | $47,040 |
| JardianceEmpagliflozin | 39 | $37,667 |
| Praluent PenAlirocumab | 12 | $16,445 |
| BrilintaTicagrelor | 22 | $14,377 |
| MounjaroTirzepatide | 13 | $13,296 |
| JanuviaSitagliptin Phosphate | 13 | $11,058 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,280 |
| Metoprolol Succinate | 264 | $4,259 |
| Rosuvastatin Calcium | 289 | $3,265 |
| Nifedipine ErNifedipine | 78 | $2,622 |
| Clonidine | 16 | $2,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $113 | $289,763281 claims |
| NovartisEntresto | $9,957 | $77,01470 claims |
| Novo NordiskOzempic | $109 | $61,07859 claims |
| Johnson & JohnsonXarelto | $290 | $47,04028 claims |
| Boehringer IngelheimJardiance | $763 | $37,66739 claims |
| AstraZenecaBrilinta | $230 | $14,37722 claims |
| MerckJanuvia | $291 | $11,05813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Plantation
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.